key: cord-0883305-v3qgqfwr
authors: Ma, Lulu; Song, Kaicheng; Huang, Yuguang
title: Coronavirus disease 2019 (COVID-19) and cardiovascular complications
date: 2020-04-30
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2020.04.041
sha: 85c748abf2e6ac5a5536f0df30d2c477462ee4e0
doc_id: 883305
cord_uid: v3qgqfwr

Abstract The coronavirus disease 2019 (COVID-19) has become a global pandemic. It has been spread to more than 100 countries and more than 1 million patients have been confirmed. Although coronavirus causes severe respiratory infections in human, accumulating data have demonstrated cardiac complications and poor outcome in patients with coronavirus disease 2019. A large percent of patients have underlying cardiovascular disease and they are at a high risk of developing cardiac complications. We review the basics of the virus, the clinical manifestation, and the possible mechanisms of cardiac complications in patients with coronavirus disease 2019. Before the effective vaccine or medicine is available, supportive therapy and identifying patients who are at high risk of cardiac complications are important.

Since the first case of the novel coronavirus (COVID- 19) firstly reported on December 31, 2019 in Wuhan, China, the rapid spread of the virus has led to a global pandemic. On March 11, the World Health Organization (WHO) declared the spread of COVID-19 had become a pandemic. On April 8 th , the cumulative numbers of diagnosed patients internationally were 1514866 with 88444 cases of mortality 1 .

With accumulating date of COVID-19, cardiac complications have become a big concern. Myocardial injury was also detected in COVID-19 patients and is confirmed to be associated with poor outcome 2 . The mortality rate among patients with underlying cardiovascular disease was 10.5%, which was much higher than that in the general population 3 

The outbreak of COVID-19 started in early December 2019 when a series of pneumonia cases of unknown causes were detected in Wuhan, China 4 .On January 7 th , the pathogen was identified as a novel coronavirus by Chinese Center for Disease Control and Prevention (CDC) and it was named 2019-nCoV by WHO on January 12, 2020 or SARS-CoV-2 by International Committee on Taxonomy of Viruses.

2019-nCoV is made of a single-stand ribonucleic acid and its genome had been 5 confirmed to be closely related with the coronavirus(SARS-CoV) which caused severe acute respiratory syndrome (SARS) 5 . Structural analysis showed 2019-nCoV had the ability to bind to the angiotensin-converting enzyme 2 receptors (ACE2) in human. The presence of ACE2 protein in the lower respiratory tract and on the enterocytes in the small intestine suggested the possible entry of the virus 6 . It has been confirmed that 2019-nCoV uses ACE2 to enter the host cell 7 .

Pneumonia and cardiac disease often present in the same patient. The association between pneumonia and cardiac complications have been confirmed previously 8,9 ,10 .

New or worsening of heart failure, arrhythmia and myocardial are common cardiac complications. 8%-25.1% community-acquired pneumonia (CAP) patients developed at least one episode of cardiac complications during their hospital stay 9, 11, 12 . Patients with underlying cardiovascular disease were more likely to develop CAP 13 .

In-hospital cardiac complications after pneumonia was associated with mortality 9 and increased cardiovascular events on 2-year follow-up 14 .

Cardiac complications have also been reported in patients with coronavirus infections 15, 16, 17 . In SARS patients, hypotension and tachycardia were common but usually self-limiting. Arrhythmia and cardiomegaly were rarely in patients diagnosed with SARS 15 . Reversible subclinical diastolic dysfunction without systolic involvement was also observed in SARS patients 16 . Acute myocarditis developed after the infection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), 6 and myocardial edema was confirmed by Magnetic Resonance Imaging (MRI).

Severe left ventricular dysfunction was persistent on 3-month follow-up 17 .

The effects of COVID-19 on the cardiovascular system are both similar and different with those of SARS and MERS. Among COVID-19 patients, cardiovascular disease is the most common comorbidities and cardiac complications are the most common complications 18, 19 .

The prevalence of hypertension and other cardiovascular disease was 15%-32.6% and 2.5%-15%, respectively 2, 18, 19, 20, 21 . Patients with underlying cardiovascular disease were more prone to develop cardiac injury 2,22 , be severely ill 18 or require intensive care 22 .

Cardiac injury, which is indicated by elevated cardiac troponin I (cTnI) had also been confirmed in COVID-19 patients. The incidence of cardiac injury ranged from7.2 % to 27.8% 2,18,19,22,23 and its incidence in ICU-patients and dead cases was 22.2% and 77%, respectively 18, 24 . Patients with elevated cTnI levels had a higher rate of cardiovascular disease 2 , and cTnI was significantly increased in severe or deceased COVID-19 patients when compared to patients with milder symptoms 2 18,19,24,25 .

Higher cTnI level was also associated with higher complications 2 and mortality 2,22 .

Elevated NT-proBNP level had be noticed 2 and patients with elevated cTnI were more likely to have elevated levels of NT-proBNP 2 . All these findings suggest the relationship between cardiac injury, cardiac dysfunction and poor outcome. And

Monitoring cardiac troponin I longitudinally during hospitalization may help predict the progression of the disease 25 .

Left ventricular dysfunction, persistent hypotension, acute myopericarditis, myocarditis, arrhythmia and heart failure have also been reported in COVID-19 patients 18, 26, 27, 28, 29 . Interstitial mononuclear inflammatory infiltration in heart tissue also provide evidence of myocarditis in COVID-19 patients 30 . However, in a recent report of case-series from critical ill patients in the Seattle region, no cardiac dysfunction was detected by echocardiograms 29 Pneumonia is a highly proinflammatory disease 28 , and elevated levels of cytokines, which included C-reactive protein (CRP), interleukin-6(IL-6), interleukin-8 (IL-8), interleukin-10(IL-10), procalcitonin, interleukin-1beta(IL-1β), Tumor necrosis factor-alpha(TNF-α), Interleukin-10(IL-10), have been detected in COVID-19 patients, especially in ICU patients 19, 33, 34 . Cytokines are important for infection control, but they can also lead to tissue damage and dysfunction(See Table 1 ). The level of cTnI was positively associated with plasma high-sensitivity CRP 2 , which suggested the possible role of inflammatory storm in the development of cardiac injury. TNF-α had been detected in patients with heart failure 35 The instability of coronary artherosclerotic plaques 45 , the increased coagulation activation 46 and platelet-aggregating activity 47 , and hypoxemia due to abnormal ventilation/perfusion(V/Q) lead to decreased myocardial oxygen supply and myocardial ischemia. Activation of sympathetic nervous system lead to increased heart rate and peripheral resistance, which will further compromise coronary perfusion 48 .

Transient disturbance of endothelial function and vascular tone 49,50 , volume overload due to impaired sodium and water metabolism 51 and cardiac arrhythmia 8 may contribute to the decreased left ventricular function or worsening of heart failure.

The role of ACE2 in the role of cardiac injury induced by COVID-19 has been proposed 22 . SARS-CoV-2 share the same host receptor(ACE2) with SARS-CoV and its affinity to ACE2 is 10 to 20 fold higher than that of SARS-CoV 52 . The use of ACEI/ARB will lead to increased expression of ACE2 and concerns about whether the use of ACEI/ARB will increase the risk of SARS-CoV-2 infection have been raised. However, in mice mode, SARS-CoV mediated myocardial injury through ACE2 with a remarkable decreased expression of ACE2 31 demonstrated there was no difference in mortality among patients with or without the use of ACEI/ARB. Before more data are available, it is not wise to discontinue ACEI/ARB in patients with COVID-19 54 .

At present, there is no effective vaccination or drug for COVID-19, only sympathetic therapy and empiric/supportive treatment are available. COVID-19 patients died due to their original comorbidities instead of pneumonia 55 , which suggested the necessity of special attention to their original comorbidities while treating pneumonia.

Whether the medications patients used for cardiovascular disease will interfere with the treatment or the outcome of COVID-19 is still unknown. The possible effects of these drugs on pneumonia were from studies on patients with CAP / other virus pneumonia. As we mentioned above, at present there is no evidence of stopping ACEI/ARB in COVID-19 patients. And previous reports about the effects of ACEI/ARB on outcome of patients with CAP were conflicting 56, 57, 58 . Statin can reduce systemic inflammation 59 and improve outcome in CAP patients 58, 59 . However, beta-blocker was associated with increased 30-day mortality and the need for mechanical ventilation in patients with CAP 59 . Calcium channel blockers, beta-blocker and thiazide were associated with a higher risk of 90-day hospitalization with pneumonia 60 . No studies have demonstrated the effect of statins, beta-blocker, 11 calcium channel blockers and diuretics on decreasing cardiac complications in patients with pneumonia.

Besides these, specific attention should be paid to medications with cardiovascular side effects for COVID-19, especially in patients with underlying cardiovascular disease. Common antibiotics, which are used for secondary bacterial infections, do exert effects on cardiovascular system. Macrolides ( for example azithromycin) 61 Chloroquine/Hydroxychloroquine, which is an old drug for malaria, has been confirmed to be effective in patients with COVID-19 62, 63 . However, their cardiotoxicity which include arrhythmia, heart failure, myocardial disorder may be severe and irreversible 64 .

Anti-inflammatory therapies have also been implied in patients with COVID-19.

Clinical trials about the effects of Tocilizumab (recombinant IL-6 monoclonal antibody) and Baricitinib (an oral-administrated selective inhibitor of the JAK1 and JAK2) on COVID-19 are recruiting patients. However, both drugs have been proven to be associated with elevated cholesterol levels 65, 66 . Although the association between altered lipid levels and cardiovascular risks is not identified, this side effect 12 can't be dismissed. Anti-PD-1 antibody, as checkpoint inhibitors has also been applied in the treatment of COVID-19(NCT04268537, NCT04333914). However, its pulmonary, cardiac and neurological toxicity, which is usually fatal, should never be underestimated. Glucocorticoids, which can suppress inflammation, has been used as empiric treatment in severe COVID-19 patients 19 . And several clinical trials are recruiting patients to evaluate its effectiveness and safety. However, corticosteroid use in patients with SARS 67 , MERS 68 and influenza 69 did not improve patients' outcome.

And it is not recommended as the treatment for COVID-19 outside of clinical trials 70 .

The COVID-19 is rapidly spreading globally. At present, we still know little about this virus. Before vaccination is available, there is no effective therapy at present. 

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

A novel coronavirus from patients with pneumonia in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Acute cardiac events in severe community-acquired pneumonia: A multicenter study

Cardiac complications in patients with community-acquired pneumonia incidence, timing, risk factors, and association with short-term mortality

Cardiac complications in patients with community-acquired pneumonia : a systematic review and meta-analysis of observational studies

The association between pneumococcal pneumonia and acute cardiac events

Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia

Association between hospitalizaiton for pneumonia and subsequent risk of cardiovascular disease

Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and 15 cardiovascular events

Cardiovascular complications of severe acute respiratory syndrome

Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study

Acute myocarditis associated with novel middle east respiratory syndrome coronavirus

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical Characteristics of Coronavirus Disease 2019 in China

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Cardiac troponin I in patients with coronavirus disease 2019(COVID-19): Evidence from a meta-analysis

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Coronavirus fulminant mypcarditis saved with glucocorticoid and human immunoglobulin

Pneumonia as a cardiovascular disease

Covid-19 in critically ill patients in the seattle region -case series

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

The continuous evolution and dissemination of 2019 novel human coronavirus

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy

Gene expression and 18 levels of IL-6 and TNFα in PBMCs correlate with severity and functional class in patients with chronic heart failure

Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-α

Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype

Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: Observations from the SOLID-TIMI 52 (stabilization of plaque using darapladib-thrombolysis in myocardial infarction 52) trial

Inflammatory biomarkers interleukin-6 and c-reactive protein and outcomes in stable coronary heart disease: Experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial

cytokines in post-infarction left ventricular remodeling

Elevated baseline plasma IL-8 levels are an independent predictor of long-term all-cause mortality in patients with acute coronary syndrome

Diagnostic and prognostic biomarkers in acute myocarditis. Interleukin-10

Serum interleukin 6 and 10 levels in Takotsubo cardiomyopathy: Increased admission levels may predict adverse events at follow-up

Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: Clues to the triggering effect of acute infections on acute coronary syndromes

Prevalence and significance of coagulation abnormalities in community-acquired pneumonia

Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection

Acute pneumonia and the cardiovascular system

Hemodynamic effects of pneumonia I.normal and hypodynamic response

Hemodynamic effects of pneumonia. II. Expansion of plasma volume

Acute infectious pneumonia is accompanied by a latent vasopressin-dependent impairment of renal water excretion

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Renin -angiotensinaldosterone aystem inhibitors in patients with Covid-19

Comorbidities and multi-organ injuries in the treatment of COVID-19

Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia

Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis

The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort

Prior statin use is associated with improved outcomes in community-acquired pneumonia

Risk of hospitalization for community acquired pneumonia with renin-angiotensin blockade in elderly patients: a population-based study

Arrhythmias associated with fluoroquinolone therapy

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials

SARS: systematic review of treatment effects

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury